Pier Capital, LLC Alx Oncology Holdings Inc Transaction History

Pier Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 15, 2023	SELL	$9.51 - $12.95 $7,313 - $9,958	-769 Reduced 0.28%	271,848 $3.06 Million
Q3 2022 Nov 15, 2022	SELL	$8.23 - $15.14 $1.03 Million - $1.89 Million	-125,128 Reduced 31.46%	272,617 $2.61 Million
Q2 2022 Aug 15, 2022	BUY	$5.89 - $19.46 $19,448 - $64,256	3,302 Added 0.84%	397,745 $3.22 Million
Q1 2022 May 10, 2022	BUY	$13.65 - $22.06 $1.27 Million - $2.06 Million	93,240 Added 30.96%	394,443 $6.67 Million
Q4 2021 Feb 10, 2022	SELL	$21.49 - $74.4 $1.62 Million - $5.61 Million	-75,362 Closed	0 $0
Q3 2021 Nov 10, 2021	BUY	$52.51 - $80.91 $3.96 Million - $6.1 Million	75,362 New	75,362 $5.57 Million

101

39.7M

134K

17.4K

Ticker ALXO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,747,100
Market Cap $74.6M
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...

Get notified when there are updates to the investment portfolio of Pier Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Pier Capital, LLC with notifications on news.